18 March 2021 in BMC Bioinformatics
JHJeanine Houwing-Duistermaat
Jeanine Houwing-Duistermaat
Background: Nowadays, multiple omics data are measured on the same samples in the belief that these different omics datasets represent various aspects of the underlying biological systems. Integrating these omics datasets will facilitate the understanding of the systems. For this purpose, various methods have been proposed, such as Partial Least Squares (PLS), decomposing two datasets into joint and residual subspaces. Since omics data are heterogeneous, the joint components in PLS will contain variation specific to each dataset. To account for this, Two-way Orthogonal Partial Least Squares (O2PLS) captures the heterogeneity by introducing orthogonal subspaces and better estimates the joint subspaces. However, the latent components spanning the joint subspaces in O2PLS are linear combinations of all variables, while it might be of interest to identify a small subset relevant to the research question. To obtain sparsity, we extend O2PLS to Group Sparse O2PLS (GO2PLS) that utilizes biological information on group structures among variables and performs group selection in the joint subspace. Results: The simulation study showed that introducing sparsity improved the feature selection performance. Furthermore, incorporating group structures increased robustness of the feature selection procedure. GO2PLS performed optimally in terms of accuracy of joint score estimation, joint loading estimation, and feature selection. We applied GO2PLS to datasets from two studies: TwinsUK (a population study) and CVON-DOSIS (a small case-control study). In the first, we incorporated biological information on the group structures of the methylation CpG sites when integrating the methylation dataset with the IgG glycomics data. The targeted genes of the selected methylation groups turned out to be relevant to the immune system, in which the IgG glycans play important roles. In the second, we selected regulatory regions and transcripts that explained the covariance between regulomics and transcriptomics data. The corresponding genes of the selected features appeared to be relevant to heart muscle disease. Conclusions: GO2PLS integrates two omics datasets to help understand the underlying system that involves both omics levels. It incorporates external group information and performs group selection, resulting in a small subset of features that best explain the relationship between two omics datasets for better interpretability.
1 January 2003 in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
本論文では, ワイヤー駆動方式で3次元空間で運動する4足ロボットの開発を行ったので報告する。まず, 歩行・走行の双方を統一的に扱うことのできる制御方式として可変拘束制御を用いた手法を紹介する。また, 提案した設計法を用いてさまざまな歩容を実現する制御則を設計し, 実験により, 設計したロボット機構の妥当性と制御則の有効性を確認を行ったので, 結果を紹介する。
1 January 2025 in BMJ Public Health
Introduction: The recommended assessment intervals for primary prevention of cardiovascular disease (CVD) differ in major international guidelines. We aimed to provide empirical evidence on the optimal frequency of CVD risk assessment to inform future guidelines. Methods: We estimated the expected time to cross the 10-year CVD risk treatment threshold of 10% using extended two-stage landmarking for more than 2 million people using UK primary care electronic health records between April 2004 and May 2019 from the Clinical Practice Research Datalink GOLD Database (CPRD GOLD), which was linked to hospital admissions data from the Hospital Episodes Statistics (HES) dataset and national mortality records from the Office for National Statistics (ONS). We grouped people based on their sex, initial risk level and age, and computed various percentiles of the expected crossing times per group. Based on the percentiles, optimal assessment intervals were identified and their performance was evaluated comparing to the current recommended intervals in the UK. Results: Our results showed that the expected crossing times for people with lower initial risk were much longer than those with higher initial risk. Within each initial risk group, expected time to crossing the risk treatment thresholds was shorter in people aged ≥65 years. Based on the median expected crossing times, our recommended intervals for women with initial 10-year risk of 7.5%–10%, 5%–7.5%, 2.5%–5% or<2.5% are 3 (1 if ≥65 years old), 7 (4), 10 (6) and 10 (10) years, respectively; intervals for men are 2 (1), 5 (5), 9 (9) and 10 (10) years. These intervals outperformed the 5-yearly risk reassessment for all individuals currently recommended in the UK. Conclusions: Our evidence suggests that CVD risk assessment intervals for primary prevention should be stratified by sex, initial risk level and age. For the UK population, our method found risk assessment intervals that reduce the number of assessments required while shortening the waiting time to the next assessment for those most in need.
21 February 2024 in Journal of Applied Statistics
In many studies of human diseases, multiple omics datasets are measured. Typically, these omics datasets are studied one by one with the disease, thus the relationship between omics is overlooked. Modeling the joint part of multiple omics and its association to the outcome disease will provide insights into the complex molecular base of the disease. Several dimension reduction methods which jointly model multiple omics and two-stage approaches that model the omics and outcome in separate steps are available. Holistic one-stage models for both omics and outcome are lacking. In this article, we propose a novel one-stage method that jointly models an outcome variable with omics. We establish the model identifiability and develop EM algorithms to obtain maximum likelihood estimators of the parameters for normally and Bernoulli distributed outcomes. Test statistics are proposed to infer the association between the outcome and omics, and their asymptotic distributions are derived. Extensive simulation studies are conducted to evaluate the proposed model. The method is illustrated by modeling Down syndrome as outcome and methylation and glycomics as omics datasets. Here we show that our model provides more insight by jointly considering methylation and glycomics.
24 December 2025 in BMC Bioinformatics
Background: In studies that aim to model the relationship between an outcome variable and multiple omics datasets, it is often desirable to reduce the dimensionality of these datasets or to represent one omics dataset in terms of another. Several approaches exist for this purpose, including univariate methods such as polygenic scores, and multivariate methods. Multivariate approaches offer advantages by producing lower-dimensional integrative scores, capturing joint structures across datasets, and filtering out dataset-specific noise. In this paper, we describe one univariate and two multivariate methods, and evaluate their performance through simulations involving two correlated multivariate normally distributed omics datasets, as well as a combination of one multivariate normal and one fixed categorical dataset. Results: We assess method performance using the root mean squared error (RMSE) when modelling the outcome variable as a function of the reduced omics representations. Multivariate methods generally perform well, particularly when a slightly higher number of components is used for integration. They outperform the univariate method in scenarios involving two normally distributed omics datasets and perform comparably in settings with one normal and one categorical dataset. In real data applications, including two metabolomics datasets from TwinsUK and a metabolomics-genetic dataset from ORCADES, all methods show similar performance in modelling body mass index. Conclusions: Multivariate methods provide a valuable framework for summarizing multi-omics datasets into low-dimensional components suitable for outcome modelling. Even in the presence of non-normal data, these methods offer a promising alternative to high-dimensional univariate approaches.